Study control, violators, inclusion criteria and defining explanatory and pragmatic trials

被引:55
作者
McMahon, AD [1 ]
机构
[1] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland
关键词
randomized controlled trial; pragmatic trial; explanatory trial; inclusion criteria; representativeness; intention to treat;
D O I
10.1002/sim.1120
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Important differences between explanatory and pragmatic studies were originally argued by Schwartz and Lellouch. Three important differences between the two types of study involve study control, study violators and inclusion criteria. It was originally argued that explanatory studies are highly controlled, and pragmatic studies may be looser and more like 'real life'. It was argued that an explanatory study should only analyse those receiving treatment, and a pragmatic study would analyse all randomized patients. Explanatory trials are said to use homogeneous groups, and pragmatic studies have less selection (better generalizability). Some suggestions are put forward to update the original distinctions between these two attitudes for future study design. Poor study control is undesirable (but might be necessary) and should not be welcomed as pragmatic. The intention-to-treat strategy is now considered as standard for nearly all trials. Homogeneity is a red herring for studies in humans. Inclusion criteria should be minimized and they should not be used to justify claims of representativeness. Routine criticism of randomized controlled trials for being unrepresentative is unwarranted. We should accept that most trials in humans are 'explanatory'. The division line should be moved, so that pragmatic studies are in the domain of non-therapeutics and complex treatments. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:1365 / 1376
页数:12
相关论文
共 69 条
[51]   LARGE-SCALE RANDOMIZED EVIDENCE - LARGE, SIMPLE TRIALS AND OVERVIEWS OF TRIALS [J].
PETO, R ;
COLLINS, R ;
GRAY, R .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (01) :23-40
[52]   PROBLEMS IN THE CONDUCT AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS - ARE WE GETTING THE RIGHT ANSWERS TO THE WRONG QUESTIONS [J].
RABENECK, L ;
VISCOLI, CM ;
HORWITZ, RI .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (03) :507-512
[53]   Pharmacoeconomic evaluation in the real world - Effectiveness versus efficacy studies [J].
Revicki, DA ;
Frank, L .
PHARMACOECONOMICS, 1999, 15 (05) :423-434
[54]  
Rochon J, 1999, DRUG INF J, V33, P1219, DOI 10.1177/009286159903300425
[55]   Understanding controlled trials -: What are pragmatic trials? [J].
Roland, M ;
Torgerson, DJ .
BRITISH MEDICAL JOURNAL, 1998, 316 (7127) :285-285
[56]  
ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P113
[57]   CAN OVERALL RESULTS OF CLINICAL-TRIALS BE APPLIED TO ALL PATIENTS [J].
ROTHWELL, PM .
LANCET, 1995, 345 (8965) :1616-1619
[58]  
SACKETT DL, 2000, CONTROLLED CLIN TRIA, V21, pS82
[59]   EXPLANATORY AND PRAGMATIC ATTITUDES IN THERAPEUTICAL TRIALS [J].
SCHWARTZ, D ;
LELLOUCH, J .
JOURNAL OF CHRONIC DISEASES, 1967, 20 (08) :637-&
[60]   FALSIFICATIONISM AND CLINICAL-TRIALS [J].
SENN, SJ .
STATISTICS IN MEDICINE, 1991, 10 (11) :1679-1692